Company / SG&A Expense
Viking Therapeutics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$48.4M
FY2025
5-year range
$10.7M / $49.3M
FY2021-FY2025
Trend
-1.8%
vs FY2024
Sector context
#163 of 213
Health Care
What the data says
Viking Therapeutics, Inc.'s sg&a expense of $48M is lower than 77% of companies in the Health Care sector (FY2025). Increased from $11M to $48M over the past 2 years.
Based on SEC 10-K filings.
$48M in FY2025 with a 5-year CAGR of +39.6%.
Increased from $11M to $48M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +65.4%
- 5-Year CAGR
- +39.6%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 213This company $48.4M Sector average $722.3M
▼
-93.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +39.6%, indicating consistent growth.
- In FY2025, sg&a expense decreased 1.8% year-over-year.
- Ranks #163 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $48.4M | -1.8% |
| FY2024 | $49.3M | +360.5% |
| FY2023 | $10.7M | +0.0% |
| FY2022 | $10.7M | -0.3% |
| FY2021 | $10.7M | +17.6% |
| FY2020 | $9.1M | +28.2% |
| FY2019 | $7.1M | +33.6% |
| FY2018 | $5.3M | +0.0% |
| FY2017 | $5.3M | +6.0% |
| FY2016 | $5.0M | +304.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026